Navigation Links
Clinical trial at GHSU Cancer Center targets advanced prostate cancer

AUGUSTA, Ga. Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.

The trial, led by GHSU Cancer Center Director Samir N. Khleif, is the first in the country to investigate prostate cancer treatment combining Provenge with two other cancer-fighting drugs, CT-011 and cyclophosphamide. As the first FDA-approved immunotherapy treatment for prostate cancer, Provenge has been found to extend life expectancy of certain men with advanced prostate cancer by nearly 20 percent.

"Although the increased overall survival seen with Provenge treatment is a welcome advance in the treatment of prostate cancer, the goal of cancer therapy must be the eradication of disease," said Khleif. "Therefore, improvements can be made, and this clinical trial is intended to improve the current standard of care."

Provenge works by training the body's immune system to find and attack prostate cancer cells. Khleif's trial hopes to boost Provenge's effectiveness by combining it with two other drugs: CT-011, a type of antibody that reverses immune suppression caused by cancer, and cyclophosphamide, which in a low dose enhances the effect of Provenge and CT-011. Both have been safely used alone or in combination with other cancer therapies, but never for prostate cancer.

Preclinical animal studies in Khleif's lab found that the combination of Provenge with these two other drugs led to a significant increase in survival and complete tumor regression in more than 50 percent of mice. Based on these results, Dendreon Corporation, the makers of Provenge, and Khleif are collaborating on this first in human trial.

Khleif joined the GHSU Cancer Center as its Director after more than 22 years in the Cancer Vaccine Section at the National Cancer Institute. His lab focuses on research into vaccines to help the immune system target and eradicate cancers.

Prostate cancer is the most common cancer and the second leading cause of cancer deaths among men in most Western countries.


Contact: Christen Carter
Georgia Health Sciences University

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. Clinical insight improves treatment with new lung cancer drug
3. Clinical news alert from the American Academy of Orthopaedic Surgeons
4. NYU Langone experts present research, clinical advances at neurosurgeons meeting
5. Kroenke honored for outstanding contributions in clinical research training
6. Awards celebrate clinical research that can improve health and alleviate suffering
7. Association for Psychological Science, SAGE launch Clinical Psychological Science
8. URMC clinical trial tests new regimen for hypertension
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
Post Your Comments:
Related Image:
Clinical trial at GHSU Cancer Center targets advanced prostate cancer
(Date:11/25/2015)... ... , ... On November 10, 2015, Bohrer Brady, LLC filed a class and ... a home health care worker who provided companionship services for the elderly, ill or ... by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), Inc. since ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published ... and more widely heralded as a breakthrough for performing hernia repairs. The article explains ... laparoscopic surgery is that it can greatly reduce the pain that a patient might ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like to become ... invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will ... , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... athletic programs, launches new Wimbledon Athletics Facebook page to educate the ... for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- Henry Schein, Inc., the world,s largest provider of health ... animal health practitioners, will unveil at the Greater New ... Pavilion , which brings together for the first time ... help any practice or laboratory enter the digital age. ... of experts appearing at the Pavilion. --> ...
(Date:11/25/2015)... 25, 2015  Trovagene, Inc. (NASDAQ: TROV ), ... Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to ... Annual Piper Jaffray Healthcare Conference. th ... Palace Hotel in New York ... Mr. Schuh will be available for one-on-one meetings during ...
(Date:11/25/2015)... 25, 2015 Endo International plc (NASDAQ: ENDP ... , President and CEO, will discuss corporate updates at the ... New York on Wednesday, December 2, 2015 ... on Investor Relations, and then the link to the event. ... start time to visit the site and download any streaming ...
Breaking Medicine Technology: